Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-Exposed Infants in Uganda
Kenneth Kintu(MUJHU Research Collaboration), Laura Guay(Johns Hopkins University), Brenda Asiimwe‐Kateera(MUJHU Research Collaboration), Lynn Baglyos(New York Blood Center), Sheryl Zwerski(National Institutes of Health), Lynda Emel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Philippa Musoke(Centers for Disease Control and Prevention), Paul Richardson(University of Liverpool), Teopista Nakyanzi(MUJHU Research Collaboration), P. Andrew(Family Health International 360), Mary Glenn Fowler(Johns Hopkins University), San-San Ou(Fred Hutch Cancer Center), J. Brooks Jackson(VA Tennessee Valley Healthcare System), Lei Wang(Shanghai Jiao Tong University), Sanjay Gurunathan(GTx (United States))
Cited by 25
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
|New England Journal of Medicine|2009|3k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557
Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine
|New England Journal of Medicine|1999|553